Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients Journal Article

Authors: Jager, E.; Karbach, J.; Gnjatic, S.; Neumann, A.; Bender, A.; Valmori, D.; Ayyoub, M.; Ritter, E.; Ritter, G.; Jäger, D.; Panicali, D.; Hoffman, E.; Pan, L.; Oettgen, H.; Old, L. J.; Knuth, A.
Article Title: Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
Abstract: NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination. © 2006 by The National Academy of Sciences of the USA.
Keywords: clinical article; unclassified drug; clinical trial; disease course; drug tolerability; drug safety; drug targeting; neoplasms; antigen expression; cd8+ t lymphocyte; cd8-positive t-lymphocytes; cancer immunotherapy; melanoma; cohort studies; neoplasm proteins; membrane proteins; drug hypersensitivity; cellular immunity; immune response; cancer vaccine; drug mechanism; cancer vaccines; cancer testis antigen; ny eso 1 antigen; immunogenicity; antibody response; cd4+ t lymphocyte; peptide fragments; vaccination; vaccines, synthetic; vaccinia virus; malignant neoplastic disease; cytotoxicity, immunologic; antibodies; drug dose regimen; humoral immunity; absence of side effects; clone cells; injection site erythema; antibody formation; recombinant vaccine; immunity, cellular; epitopes; injection site pruritus; t cell response; vaccinia vaccine; virus vaccine; fowlpox virus; ny-eso-1 recombinant vaccine; tumor reactivity; fowlpox vaccine; recombinant fowlpox ny eso 1 antigen vaccine; recombinant vaccinia ny eso 1 antigen vaccine
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Volume: 103
Issue: 39
ISSN: 0027-8424
Publisher: National Academy of Sciences  
Date Published: 2006-09-26
Start Page: 14453
End Page: 14458
Language: English
DOI: 10.1073/pnas.0606512103
PUBMED: 16984998
PROVIDER: scopus
PMCID: PMC1570182
Notes: --- - "Cited By (since 1996): 98" - "Export Date: 4 June 2012" - "CODEN: PNASA" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Sacha Gnjatic
    111 Gnjatic
  2. Gerd Ritter
    159 Ritter
  3. Erika Ritter
    34 Ritter
  4. Herbert F Oettgen
    15 Oettgen
  5. Lloyd J Old
    393 Old